Urteste SA Total Assets
Urteste SA total assets. Based on the latest financial reports, Urteste SA (URT) holds total assets worth zł40.53 Million PLN (≈ $11.16 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of Urteste SA for how efficiently the company converts equity into cash flow.
Total Assets of Urteste SA (2019–2025)
Total assets of Urteste SA from 2019 to 2025. This chart illustrates how Urteste SA's total assets have evolved over time, based on quarterly financial data. See Urteste SA stock price for real-time trading data and today's change.
Urteste SA - Asset Composition Analysis
Urteste SA Total Assets Breakdown (December 2025)
Urteste SA total assets breakdown as of December 2025. Urteste SA's total assets of zł40.53 Million consist of 45.6% current assets and 54.4% non-current assets. Explore URT working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 19.6% |
| Accounts Receivable | zł5.73 Million | 12.7% |
| Inventory | zł0.00 | 0.0% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł22.07 Million | 48.9% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Urteste SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Urteste SA's current assets represent 45.6% of total assets in 2025, an increase from 20.3% in 2019.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2025, up from 14.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 48.9% of total assets.
Urteste SA Competitors by Total Assets
Key competitors of Urteste SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Urteste SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.58 | 13.48 | 57.53 |
| Quick Ratio | 2.58 | 13.48 | 57.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł8.13 Million | zł14.35 Million | zł3.19 Million |
Urteste SA - Advanced Valuation Insights
This section examines the relationship between Urteste SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.74 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 52.4% |
| Total Assets | zł45.14 Million |
| Market Capitalization | $17.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Urteste SA's assets below their book value (0.39x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Urteste SA's assets grew by 52.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Urteste SA (2019–2025)
The table below shows the annual total assets of Urteste SA from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł45.14 Million ≈ $12.42 Million |
+52.40% |
| 2024-12-31 | zł29.62 Million ≈ $8.15 Million |
+0.07% |
| 2023-12-31 | zł29.60 Million ≈ $8.15 Million |
+342.16% |
| 2022-12-31 | zł6.69 Million ≈ $1.84 Million |
-32.66% |
| 2021-12-31 | zł9.94 Million ≈ $2.74 Million |
+618.59% |
| 2020-12-31 | zł1.38 Million ≈ $380.69K |
+11.62% |
| 2019-12-31 | zł1.24 Million ≈ $341.07K |
-- |
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers in Poland. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.